If You Invested in Ainos, Inc. (AIMD)
Looking for the current price? See the AIMD quote & overviewWhat $1,000 or $10,000 in AIMD Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jan 11, 2021 |
|---|---|---|---|---|
| $1,000 | $581 -42% | $4.55 -99.54% | — | $16 -98% |
| $10,000 | $5,812 -42% | $46 -99.54% | — | $161 -98% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-19. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for AIMD$1,000 Investment Over Time
AIMD vs S&P 500Year-by-Year Returns
AIMD annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021Jan 11 to Dec 31 | $69.00 | $315.02 | +356.5% | +356.5% |
| 2022 | $315.02 | $15.50 | -95.1% | -77.5% |
| 2023 | $15.50 | $10.25 | -33.9% | -85.1% |
| 2024 | $10.25 | $2.28 | -77.8% | -96.7% |
| 2025 | $2.28 | $1.64 | -28.1% | -97.6% |
| 2026Dec 31, 2025 to Nov 19 | $1.64 | $1.11 | -32.3% | -98.4% |
About Ainos, Inc.
Technology · NASDAQ
Ainos, Inc. (NASDAQ: AIMD) is a Texas-incorporated company that has transitioned from its historical biotechnology focus into a technology-driven business centered on AI-powered digital olfaction. The company describes itself as a dual-platform AI and biotech company, combining its SmellTech platform, branded as AI Nose, with development of VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos’ shares trade on the Nasdaq Stock Market under the symbol AIMD, with associated warrants trading under AIMDW.
Ainos’ core technology platform, AI Nose, digitizes scent into Smell ID, a machine-readable data format that allows artificial intelligence systems to interpret olfactory information. The platform integrates precision MEMS sensor arrays with proprietary AI algorithms to create a full-stack electronic nose (e‑nose) system. According to company disclosures, AI Nose is designed to support parts-per-billion (ppb) level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured data, while Ainos’ Smell Language Model (SLM) is designed to classify, contextualize, and learn complex scent patterns over time.
SmellTech Platform and Dual-Engine Architecture
Ainos has articulated a dual-engine SmellTech architecture that separates the physical sensing layer from the AI intelligence layer. Within this structure, Ainos focuses on designing, manufacturing, and deploying AI Nose sensing hardware, including control over sensor design, firmware, calibration, manufacturing processes, quality assurance, and global certifications. Its wholly owned subsidiary, ScentAI Inc., operates as a pure AI software company dedicated to developing the Smell Language Model and related AI systems that transform scent data into Smell ID and higher-level intelligence.
The company states that this structural separation is intended to support scalability, governance clarity, and long-term platform durability. Ainos concentrates on physical deployment and data generation at the edge of the physical world, while ScentAI focuses on data abstraction, model training, and intelligence delivery through mechanisms such as enterprise APIs, SaaS offerings, and model licensing. The two entities are described as complementary layers within a unified SmellTech platform, rather than competitors at the product or customer level.
Commercialization Strategy and SmellTech-as-a-Service
Ainos is positioning AI Nose under a SmellTech-as-a-Service model. Company materials describe subscription-based deployment approaches that provide ongoing access to scent intelligence, analytics, and AI-driven insights. AI Nose is intended to support continuous monitoring, predictive analysis or analytics, and real-time alerts across industrial and manufacturing environments. The company has highlighted applications in semiconductor manufacturing, smart factories, robotics, healthcare, senior care, hospital infection control, and environmental monitoring, among others, where real-time environmental sensing and process stability are important.
According to Ainos’ public statements, the platform is being deployed in advanced semiconductor environments, including both back-end processes and front-end wafer fabrication. The company has entered into a distribution and deployment agreement with Trusval Technology, a Taiwan-based engineering and technical services provider specializing in semiconductor manufacturing environments. Under this agreement, Trusval serves as an authorized sales agent and deployment partner for AI Nose in defined semiconductor front-end applications, with a contractually defined initial minimum purchase commitment of 600 AI Nose units intended to support deployment in wafer fabrication facilities.
Industrial and Edge AI Partnerships
Ainos has reported an expanding ecosystem of industrial partners across semiconductors, robotics, automation, and smart manufacturing. The company has announced partnerships with firms such as NEXCOM International Co., Ltd., a provider of industrial computing and edge AI solutions. Under that collaboration, Ainos supplies AI Nose hardware and software for integration into NEXCOM’s edge AI and automation systems, with the goal of enabling real-time environmental sensing and intelligent monitoring across manufacturing and industrial applications.
Through these collaborations, AI Nose is being positioned as a scent-based edge AI solution that can process olfactory data locally at the edge rather than exclusively in the cloud. Company materials state that this approach is intended to reduce latency, support data privacy, and provide instant insights for applications such as predictive maintenance, intelligent monitoring, and sustainability-related operations. Ainos has also highlighted that its industrial ecosystem includes multiple partners in semiconductors, robotics, and smart manufacturing, and that it has showcased AI Nose modules at industry exhibitions such as SEMICON Taiwan.
Intellectual Property and Data Moat
Ainos reports a growing intellectual property portfolio around AI Nose and digital olfaction. The company has disclosed securing patents in the U.S., Europe, Germany, Japan, Taiwan, and China, and has stated that it holds 123 active patents and applications covering key technologies related to AI Nose, including product design, internal structures, system configurations, and operating principles. Recent announcements describe additional patents in Europe, Germany, Taiwan, and China that strengthen applications in robotics.
The company also emphasizes a long-term scent data moat, citing more than a decade of accumulated real-world scent data across medical, industrial, and environmental settings. This dataset underpins the training of the Smell Language Model and the development of Smell ID. Ainos presents this combination of patents and data as central to its competitive positioning in AI-powered electronic nose technologies and digital olfaction.
Sector Classification and Strategic Focus
Historically associated with biotechnology, Ainos has disclosed a Global Industry Classification Standard (GICS) reclassification to the Technology Hardware, Storage & Peripherals industry within the information technology sector. The company links this reclassification to its transformation into a technology company focused on AI-powered scent digitization and digital olfaction infrastructure. It has also referenced the establishment of a Smart Healthcare Sensing division to advance AI Nose’s healthcare applications.
Ainos continues to describe itself as a dual-platform AI and biotech company, reflecting its ongoing development of VELDONA, a low-dose oral interferon candidate targeting rare, autoimmune, and infectious diseases. In parallel, the company is building its SmellTech platform as an AI infrastructure layer intended to allow machines and industrial systems to interpret scent as a structured data language.
Corporate Structure and Headquarters
Ainos, Inc. is organized as a Texas corporation. SEC filings list the company’s principal executive offices in San Diego, California, and the company has announced plans to relocate its U.S. headquarters to Houston, Texas in early 2026. The relocation is described as a step to improve operating efficiency and to position Ainos within a technology and industrial innovation hub that aligns with its focus on advanced manufacturing, energy, healthcare, robotics, and AI.
The company has also formed ScentAI Inc. as a wholly owned subsidiary to advance its smell language model and AI software platform. ScentAI is expected to be co-located with Ainos’ headquarters to maintain close coordination between AI model development and AI Nose hardware deployed in the field.
Business Model and Revenue Approach
Ainos’ disclosures describe a business model that combines hardware deployment of AI Nose devices with software and data services enabled by ScentAI. The company has referenced SmellTech-as-a-Service subscription contracts and multi-year deployment agreements in industrial settings, including semiconductor manufacturing. It has also reported pilot programs in elderly care and senior care environments, as well as pilot deployments with a robotic partner in Japan.
According to company statements, AI Nose deployments generate continuous scent data that feeds into the Smell Language Model, creating a feedback loop in which broader deployment improves model performance, and improved models support further adoption. This feedback loop is described as a data flywheel that underlies the company’s long-term platform strategy.
Biotech Platform: VELDONA
Alongside its SmellTech activities, Ainos continues to develop VELDONA, described as a low-dose oral interferon candidate targeting rare, autoimmune, and infectious diseases. The company presents VELDONA as part of its biotech platform, complementing its AI and SmellTech initiatives. Public materials note that Ainos’ research and development spending supports both the SmellTech platform and its clinical programs, though detailed clinical results or regulatory milestones are not provided in the supplied information.
Stock Information and Governance
Ainos’ common stock trades on the Nasdaq Stock Market under the symbol AIMD, and its warrants trade under AIMDW. The company files periodic reports, proxy statements, and current reports with the U.S. Securities and Exchange Commission. A recent definitive proxy statement describes matters such as director elections, auditor ratification, and approval of special stock awards, indicating an active governance and shareholder voting process.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Ainos, Inc. investment returns
How much would $1,000 invested in Ainos, Inc. be worth today?
If you invested $1,000 in Ainos, Inc. (AIMD) 5 years ago on 2021-11-22, your investment would be worth $4.55 as of 2026-11-19, a -99.5% price return without dividends, growing at a compounded rate of -66.0% per year (CAGR).
Has Ainos, Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare AIMD performance over available time periods.
What is Ainos, Inc.'s average annual return?
The compound annual growth rate (CAGR) of AIMD’s share price over the past 5 years is -66.0%, without dividends. Individual years vary a great deal, and AIMD’s best recent full year was 2025 (-28.1%) while the worst was 2022 (-95.1%).
For informational and educational purposes only, not investment advice.